TY - JOUR
T1 - Cost Comparisons between Different Techniques of Percutaneous Renal Biopsy for Small Renal Masses
AU - Dutta, Rahul
AU - Okhunov, Zhamshid
AU - Vernez, Simone L.
AU - Kaler, Kamaljot
AU - Gulati, Anjalie T.
AU - Youssef, Ramy F.
AU - Nelson, Kari
AU - Lotan, Yair
AU - Landman, Jaime
N1 - Publisher Copyright:
© Copyright 2016, Mary Ann Liebert, Inc. 2016.
PY - 2016/5
Y1 - 2016/5
N2 - Purpose: To compare the costs associated with ultrasound (US)-guided hospital-based (UGHB), CT-guided hospital-based (CTG), and US-guided office-based (UGOB) percutaneous renal biopsy (PRB) for small renal masses (SRMs). Methods: We retrospectively analyzed patient demographics, tumor characteristics, R.E.N.A.L. nephrometry scores, and cost data of patients undergoing PRB for SRM at our institution from May 2012 to September 2015. Cost data, including facility costs, professional fees, and pathology, were obtained from the departments of urology, radiology, and pathology. Results: A total of 78 patients were included in our analysis: 19, 31, and 28 UGHB, CTG, and UGOB, respectively. There was no difference in age, gender distribution, or tumor size among the three groups (p-values 0.131, 0.241, and 0.603, respectively). UGOB tumors had lower R.E.N.A.L. nephrometry scores (p = 0.008). There were no differences in nondiagnostic rates between the UGHB, CTG, and UGOB groups [4 (21%), 5 (16%), and 6 (21%)] (p = 0.852). There were no differences in final tumor treatment strategies utilized among the UGHB, CTG, and UGOB groups (p = 0.447). There were 0, 2 (6%), and 0 complications in the UGHB, CTG, and UGOB biopsy groups. Total facility costs were $3449, $3280, and $1056 for UGHB, CTG, and UGOB PRB, respectively (p < 0.0001). There was no difference between the urologist's and radiologist's professional fees (p = 0.066). Total costs, including facility costs, pathology fees, and professional fees, were $4598, $4470, and $2129 for UGHB, CTG, and UGOB renal biopsy, respectively (p < 0.0001). Conclusion: For select patients with less anatomically complex, exophytic, and posteriorly located tumors, UGOB PRB provides equivalent diagnostic and complication rates while being significantly more cost-effective than either UGHB or CTG renal biopsy.
AB - Purpose: To compare the costs associated with ultrasound (US)-guided hospital-based (UGHB), CT-guided hospital-based (CTG), and US-guided office-based (UGOB) percutaneous renal biopsy (PRB) for small renal masses (SRMs). Methods: We retrospectively analyzed patient demographics, tumor characteristics, R.E.N.A.L. nephrometry scores, and cost data of patients undergoing PRB for SRM at our institution from May 2012 to September 2015. Cost data, including facility costs, professional fees, and pathology, were obtained from the departments of urology, radiology, and pathology. Results: A total of 78 patients were included in our analysis: 19, 31, and 28 UGHB, CTG, and UGOB, respectively. There was no difference in age, gender distribution, or tumor size among the three groups (p-values 0.131, 0.241, and 0.603, respectively). UGOB tumors had lower R.E.N.A.L. nephrometry scores (p = 0.008). There were no differences in nondiagnostic rates between the UGHB, CTG, and UGOB groups [4 (21%), 5 (16%), and 6 (21%)] (p = 0.852). There were no differences in final tumor treatment strategies utilized among the UGHB, CTG, and UGOB groups (p = 0.447). There were 0, 2 (6%), and 0 complications in the UGHB, CTG, and UGOB biopsy groups. Total facility costs were $3449, $3280, and $1056 for UGHB, CTG, and UGOB PRB, respectively (p < 0.0001). There was no difference between the urologist's and radiologist's professional fees (p = 0.066). Total costs, including facility costs, pathology fees, and professional fees, were $4598, $4470, and $2129 for UGHB, CTG, and UGOB renal biopsy, respectively (p < 0.0001). Conclusion: For select patients with less anatomically complex, exophytic, and posteriorly located tumors, UGOB PRB provides equivalent diagnostic and complication rates while being significantly more cost-effective than either UGHB or CTG renal biopsy.
UR - http://www.scopus.com/inward/record.url?scp=84969674557&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969674557&partnerID=8YFLogxK
U2 - 10.1089/end.2016.0015
DO - 10.1089/end.2016.0015
M3 - Article
C2 - 26915901
AN - SCOPUS:84969674557
SN - 0892-7790
VL - 30
SP - S28-S33
JO - Journal of endourology
JF - Journal of endourology
ER -